The news is by your side.


AstraZeneca rebuilds cancer drug hopes with new lung data

MADRID: Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July’s big clinical trial setback in the disease. Particularly notable was the success of the infused immunotherapy medicine Imfinzi in helping non-small cell lung cancer patients with inoperable mid-stage disease that has not spread widely around the body. Chief Executive Pascal Soriot said it gave AstraZeneca a chance to intervene earlier in lung cancer,…